An indirect comparison, via enoxaparin, of rivaroxaban with dabigatran in the prevention of venous thromboembolism after hip or knee replacement

by Symmetron | Jan 21, 2019

Venous Thromboembolism   An indirect comparison, via enoxaparin, of rivaroxaban with dabigatran in the prevention of venous thromboembolism after hip or knee replacement Journal of Medical Economics. 2011;14(2):238-44 Authors Lereun C, Wells P, Diamantopoulos A, Rasul...

Cost–effectiveness of rivaroxaban versus heparins for prevention of venous thromboembolism after total hip or knee surgery in Sweden

by Symmetron | Jan 21, 2019

Venous Thromboembolism   Cost-effectiveness of rivaroxaban versus heparins for prevention of venous thromboembolism after total hip or knee surgery in Sweden Expert Review of Pharmacoeconomics and Outcomes Research. 2011;11(5):601-15 Authors Ryttberg L, Diamantopoulos...

Cost and outcomes associated with rivaroxaban vs enoxaparin for the prevention of postsurgical venous thromboembolism from a US payer’s perspective

by Symmetron | Jan 21, 2019

Venous Thromboembolism   Cost and outcomes associated with rivaroxaban vs enoxaparin for the prevention of postsurgical venous thromboembolism from a US payer’s perspective Journal of Medical Economics. 2011;14(6):824-34 Authors Duran A, Sengupta N,...

Cost effectiveness of rivaroxaban versus enoxaparin for prevention of post-surgical venous thromboembolism from a U.S. payer’s perspective

by Symmetron | Jan 21, 2019

Venous Thromboembolism   Cost Effectiveness of Rivaroxaban versus Enoxaparin for Prevention of Post-Surgical Venous Thromboembolism from a US Payer’s Perspective. PharmacoEconomics. 2012;30(2):87-101 Authors Duran A, Sengupta N, Diamantopoulos A, Forster F, Kwong L,...

Cost-effectiveness of rivaroxaban in the prevention of venous thromboembolism: A Canadian analysis using the Ontario Ministry of Health Perspective

by Symmetron | Jan 19, 2019

Venous Thromboembolism   Cost-effectiveness of rivaroxaban in the prevention of venous thromboembolism: A Canadian analysis using the Ontario Ministry of Health Perspective Journal of Medical Economics. 2012;15(5):817-28 Authors McDonald H, Diamantopoulos A, Wells P,...